Mumbai, May 23 -- Under this strategic agreement, Orion Corporation will serve as the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe. As part of the deal, Shilpa is entitled to receive development and regulatory milestone payments from Orion.

Shilpa has been investing in the development of this novel product for approximately eight years, including the establishment of a large-scale fermentation facility designed to manufacture recombinant human albumin. This facility aims to meet the global demand for this life-saving drug. The collaboration with Orion marks a major milestone in Shilpa's expansion into the global biosimilar and biopharmaceutical markets, leveraging Orion's st...